Contrasting Cambrex (CBM) and Its Rivals

Cambrex (NYSE: CBM) is one of 101 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Cambrex to related companies based on the strength of its analyst recommendations, profitability, valuation, risk, institutional ownership, earnings and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Cambrex and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cambrex 0 0 3 0 3.00
Cambrex Competitors 887 3829 6812 182 2.54

Cambrex currently has a consensus price target of $62.33, indicating a potential upside of 28.26%. As a group, “Pharmaceuticals” companies have a potential upside of 16.76%. Given Cambrex’s stronger consensus rating and higher possible upside, research analysts plainly believe Cambrex is more favorable than its competitors.

Earnings and Valuation

This table compares Cambrex and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cambrex $490.64 million $81.67 million 16.20
Cambrex Competitors $8.17 billion $1.09 billion 155.65

Cambrex’s competitors have higher revenue and earnings than Cambrex. Cambrex is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

43.9% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 2.5% of Cambrex shares are owned by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Cambrex and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cambrex 18.79% 23.42% 16.19%
Cambrex Competitors -2,542.09% -73.52% -8.12%

Volatility and Risk

Cambrex has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Comparatively, Cambrex’s competitors have a beta of 34.16, suggesting that their average stock price is 3,316% more volatile than the S&P 500.

Summary

Cambrex competitors beat Cambrex on 7 of the 13 factors compared.

About Cambrex

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit